MD Medical Research

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes7 trials
• Gout5 trials
• Chronic kidney disease2 trials
• Heart failure2 trials
• High blood pressure2 trials
• Obesity2 trials
• Alzheimer disease1 trial
• Coronary artery disease1 trial
• Diabetic eye disease1 trial
• Familial hypercholesterolaemia1 trial
• Lyme disease1 trial
• Osteoarthritis1 trial
• and 1 more

Phase

• Phase 312 trials
• Phase 27 trials
• Phase 42 trials
• Phase 1/21 trial

Status

• Completed11 trials
• Active, not recruiting6 trials
• Recruiting5 trials

Lead sponsor

• Novo Nordisk A/S5 trials
• Amgen3 trials
• Novartis Pharmaceuticals3 trials
• Boehringer Ingelheim2 trials
• Eli Lilly and Company2 trials
• and 6 more

Running trials

• Recruiting

  Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

  NCT07830719· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Marie Edwards

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

  NCT07535034· Phase 2· Crystalys Therapeutics· Source

  Contact: Stephen Ong, MD

• Recruiting

  A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

  NCT07388498· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· Phase 3· NewAmsterdam Pharma· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

  NCT05224102· Phase 4· Genentech, Inc.· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gout2 recruiting
• Type 2 diabetes2 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting

Closed trials

• Completed

  A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

  NCT06828666· Phase 1/2· Britecyte· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06542874· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Phase 3· Pfizer· Source

• Completed

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

  NCT05586958· Phase 3· LG Chem· Source

• Completed

  A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

  NCT05486065· Phase 2· Novo Nordisk A/S· Source

• Completed

  Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

  NCT04511702· Phase 4· Amgen· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source